Clinical trials
Follow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Company intelligence / Profile preview
SunAct Cancer Institute
Mumbai, Maharashtra, India
- Ownership
- Private
- Development stage
- Other
01
Overview
SunAct Cancer Institute is conducting a Phase 2 clinical trial (jointly with CytoMed Therapeutics) evaluating allogeneic gamma delta T cell therapy for solid tumors and other cancers. Preliminary results include India’s first successful use of allogeneic CAR-T for solid tumors; further trials underway with focus on safety, tolerability, and efficacy, though no published clinical trial outcomes are yet available.
- Therapeutic areas
- HematologyOncology
- Modalities
- CAR-T cell therapyGene therapyCRISPR-based therapyImmunotherapyStem cell therapyBone marrow transplantT cell receptor engineered T cell therapyGamma delta T cell therapy
- Industry
- Academic Hospital/University/Research
02
Partnerships
Smita Memorial Hospital & Research CentreCytoMed Therapeutics
Beyond the preview
Go deeper on SunAct Cancer Institute.
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Licensing & deals
Explore licensing agreements, acquisitions, and the assets behind each deal.
- Partners
- Deal terms
- Milestones
Funding history
Trace financing activity and the investors behind a company’s development.
- Funding rounds
- Investors
- Capital raised
Competitive landscape
Compare peer pipelines by target, modality, and therapeutic area.
- Peer companies
- Targets
- Pipeline overlap
Technologies & patents
Explore technology platforms and the patent landscape around relevant assets.
- Platforms
- Patents
- Assignees
Research & analysis
Connect company news and source material to the questions you’re investigating.
- Company news
- Sources
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on SunAct Cancer Institute.